ECOVAXXIN® MG marketing authorisation application
Summary by AI BETAClose X
11 November 2026
ECO Animal Health Group plc
(“ECO” or the “Company”)
Submission of EU marketing authorisation application for ECOVAXXIN® MG
ECO Animal Health Group plc (AIM: EAH), a leading global animal health company developing and marketing branded veterinary products to improve livestock productivity and welfare, announces that it has submitted a Marketing Authorisation Application and supporting dossier to the European Medicines Agency (“EMA”) for ECOVAXXIN® MG, its live poultry vaccine targeting Mycoplasma gallisepticum.
ECOVAXXIN® MG is the second vaccine product from ECO’s proprietary R&D pipeline to be submitted for marketing authorisation to the EMA. It follows ECOVAXXIN® MS, the Company’s poultry vaccine against Mycoplasma synoviae, which was commercially launched in the EU in July 2026. If approved, ECOVAXXIN® MG will extend ECO’s poultry vaccine offering across major Mycoplasma infections and will sit alongside Aivlosin®, the Company’s market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry.
In March 2026, ECOVAXXIN® MG received a favourable safety assessment from the United States Department of Agriculture, marking an important step towards achieving marketing authorisation for the vaccine in the United States.
David Hallas, Chief Executive Officer of ECO Animal Health, said: “The submission of the EU dossier for ECOVAXXIN® MG is an important milestone for ECO and reflects the hard work and commitment of our R&D and regulatory teams. Following the EU approval and launch of ECOVAXXIN® MS, ECOVAXXIN® MG builds on our position in the prevention and treatment of Mycoplasma infection in poultry. Our regulatory plan remains in-line with expectations and we look forward to progressing through the EMA review process and advancing towards a planned launch, while in parallel continuing our work towards US marketing authorisation.”
Mycoplasma gallisepticum is a bacterial pathogen responsible for chronic respiratory disease in chickens which causes decreased egg production leading to major economic losses in poultry. The live strain of the bacteria used for ECOVAXXIN® MG is a naturally attenuated isolate shown to be safe for young chicks.
-Ends-
Contacts
|
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
|
|
|
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson Phillip Marriage
|
020 3709 5700
|
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Jen Boorer Sara Hale James Fischer
|
020 7496 3000 |
|
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden
|
020 3100 2000
|
|
Equity Development Hannah Crowe Matt Evans |
020 7065 2692 |
|
|
|
About ECO Animal Health
ECO Animal Health (AIM: EAH) is a leading global animal health company, developing and marketing branded veterinary products that optimise livestock wellbeing and productivity.
The Group’s proprietary lead product, Aivlosin® is a market leading antibiotic for the treatment of respiratory and intestinal diseases in pigs and poultry, distributed to over 70 markets through an established commercial platform.
ECO Animal Health is also investing in the next generation of animal health products through a self-funded R&D pipeline, with a particular focus on prevention and vaccines. The first product from ECO’s pipeline, ECOVAXXIN® MS, a poultry vaccine targeting Mycoplasma synoviae infection, was commercially launched in the EU in July 2026.
Headquartered in the UK, with a global presence, ECO Animal Health employs over 200 people worldwide.
View the Group’s website or LinkedIn page for further information.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 11 minutes ago Savills
- 31 minutes ago Everyman Media Group
- 1 hour ago Croda International
- 2 hours ago Diageo
- 2 hours ago IMI